Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Agilis and Intrexon to Pursue Transformative Therapies for Rare Genetic Disease

Published: Friday, January 03, 2014
Last Updated: Friday, January 03, 2014
Bookmark and Share
Exclusive channel collaboration focused on DNA-based therapeutics for children and adults with Friedreich’s ataxia.

Agilis Biotherapeutics, LLC and Intrexon Corporation have announced an Exclusive Channel Collaboration (ECC) to develop DNA-based therapeutics for Friedreich’s ataxia (FRDA), a rare genetic neurodegenerative disease.

Agilis and Intrexon expect DNA-based therapeutics to provide the ability to target underlying disease mechanisms with precision using tightly-controlled gene therapies for patients with rare inherited diseases such as FRDA.

Current FRDA therapies are primarily focused on supportive care and symptom relief. There are no FDA-approved treatment options to address the cause of FRDA.

The technical core of Agilis’ novel DNA-based therapeutics will utilize Intrexon’s UltraVector® platform and RheoSwitch Therapeutic System® (RTS®) to develop gene therapies and
Genetically-modified cell therapies for treating FRDA.

The ECC’s planned approach to target FRDA will employ RTS®, a clinically validated inducible gene switch technology that regulates the expression of therapeutic proteins or bioactive RNA in a dose-dependent fashion.

FRDA is an inherited disease caused by a gene mutation that reduces the expression of frataxin, a protein localized in the “power center” of cells known as the mitochondria, and results in a physically debilitating, life-shortening condition. Progression of the disease causes nervous system damage, problems with movement and early death most often caused by cardiac malfunction. FRDA is the most common hereditary ataxia with an estimated 5,000 to 10,000 patients in the United States.

The goal of the ECC is to develop DNA-based therapeutics to repair or replace the “broken” gene in FRDA and enable increased production of the frataxin protein to alleviate the downstream effects of frataxin deficiency. The combination of gene correction with additional therapeutic modulators in a multigenic approach has the potential to create a potent treatment. This treatment is expected to further improve cardiovascular and neurological function by addressing the underlying causes of FRDA and associated symptoms. Agilis also has an option to advance a second undisclosed rare disease indication.

“We are thrilled to be working with Intrexon with the hope of providing children and adults affected with rare genetic disorders with promising new treatments,” said George S. Zorich, Chief Executive Officer of Agilis Biotherapeutics. “We believe Agilis is on the forefront of one of the most promising treatment breakthroughs for Friedreich’s ataxia. I am personally excited to
collaborate with the Intrexon team and look forward to developing new transformative therapies together.”

Samuel Broder, M.D., Senior Vice President of Intrexon’s Health Sector and former Director of the National Cancer Institute, said “FRDA causes heart failure and progressive neurological
deterioration, which in turn cause suffering and premature deaths. The goal of this collaboration is to harness Intrexon’s proprietary technologies in synthetic DNA, as well as our expertise in molecular, protein, and cellular engineering, to benefit patients with this very serious disorder.”

Intrexon Founder and Chief Science Officer Thomas Reed, Ph.D., remarked that unlike some biotechnology companies which are limited to single classes of therapeutic molecules or gene delivery systems, Intrexon is equipped to pursue several different therapeutic approaches for treating the complexities associated with FRDA.

“As an inventor and integrator of technology platforms, we will make use of our UltraVector® multi-gene engineering, RTS® gene switch, advanced Protein Engineering, and other platforms
to develop therapeutic candidates designed to treat both the neurological and the cardiovascular pathologies of FRDA. We are confident that our ability to pursue multiple approaches for treating this complex disease will significantly increase our probability of success.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
World’s Largest Coral Gene Database
‘Genetic toolkit’ will help shed light on which species survive climate change.
Early Genetic Changes in Premalignant Colorectal Tissue Identified
Findings point to drivers of early cancer development, targets for cancer prevention therapies.
Scientists Find Evidence That Cancer Can Arise Changes
Researchers at Rockefeller University have found a mutation that affects the proteins that package DNA without changing the DNA itself can cause a rare form of cancer.
Modified Microalgae Converts Sunlight into Valuable Medicine
A special type of microalgae can soon produce valuable chemicals such as cancer treatment drugs and much more just by harnessing energy from the sun.
Breakthrough Approach to Breast Cancer Treatment
Scripps scientists have designed a drug candidate that decreases growth of breast cancer cells.
Loss Of Y Chromosome Increases Risk Of Alzheimer’s
Men with blood cells that do not carry the Y chromosome are at greater risk of being diagnosed with Alzheimer’s disease. This is in addition to an increased risk of death from other causes, including many cancers. These new findings by researchers at Uppsala University could lead to a simple test to identify those at risk of developing Alzheimer’s disease.
A Guide to CRISPR Gene Activation
A comparison of synthetic gene-activating Cas9 proteins can help guide research and development of therapeutic approaches.
Gene That Lowers Heart Attack Risk Identified
Individuals with a rare twelve-letter deletion from a gene on chromosome 17 have significantly reduced non-HDL cholesterol levels and a 35% lower than average risk of heart disease.
Testing Non-Breast/Ovarian Cancer Genes
Researchers have found that expanding gene panel beyond breast/ovarian cancer genes in these patients does not add any clinical benefit. Instead, testing has produced more questions than answers.
Myeloid-Derived Suppressor Cells Play Role in Tumor Growth
Researchers at Baylor College of Medicine have reported a new mechanism that helps cancer cells engage myeloid-derived suppressor cells.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!